Glycomine
2013
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$33M
LATEST DEAL AMOUNT
9
INVESTORS
Description
Developer of nano medicines designed to develop a new generation of replacement therapies for rare diseases. The company's medicines include orphan drugs that combine replacement therapies such as substrates, enzymes or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to treat their patients for serious rare monogenic disorders of metabolism and protein misfolding.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- MBC BioLabs
- 733 Industrial Road
- San Carlos, CA 94070
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Glycomine’s full profile, request a free trial.
Glycomine Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 07-Aug-2019 | $33M | 0000 | 0000 | Completed | Clinical Trials - General |
| 3. Early Stage VC (Series A) | 16-Nov-2016 | 0000 | 0000 | 000.00 | Completed | Generating Revenue |
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Glycomine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 1,337,056 | $0.000100 | $3.8 | $3.8 | 1x | $3.8 | 2.16% |
Glycomine Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MiNA Therapeutics | Venture Capital-Backed | London, United Kingdom | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 0000 | |
| 0000000 0000000000 | Venture Capital-Backed | La Jolla, CA | 00000 | 00000000000 | 00000 | |
| 00000000 000000000 | Venture Capital-Backed | Boston, MA | 000 | 00.000 | 000000000 | 00.000 |
| 0000000 0000000000 | Formerly VC-backed | London, United Kingdom | 00 | 00000 | 000000000 | 00000 |
Glycomine Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Asahi Kasei Pharma America | Corporation | Minority | 000 0000 | 000000 0 | ||
| Mission Bay Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Novo Holdings | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Chiesi Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Matt Wilsey | Angel (individual) | Minority | 000 0000 | 000000 0 |
Glycomine Executive Team (4)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Peter McWilliams Ph.D | Chief Executive Officer & Board Member | ||
| Matt Wilsey | Advisor | ||
| Patrice Rioux MD | Chief Medical Officer |
1 Former Executive
You’re viewing 3 of 4 executives. Get the full list »Glycomine Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Christopher Starr Ph.D | Self | Board Member | 000 0000 | |
| Fred Middleton | Sanderling Ventures | Board Member | 000 0000 | |
| Giacomo Chiesi | Chiesi Ventures | Board Member | 000 0000 | |
| Kenneth Harrison Ph.D | Novo Holdings | Board Member | 000 0000 | |
| Peter McWilliams Ph.D | Glycomine | Chief Executive Officer & Board Member | 000 0000 |